Business Context and Reporting Period
This Form 8-K is a current report filed by pSivida Corp. (not Eyepoint, Inc.) on July 18, 2013. The filing discloses the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 3,494,550 shares of common stock.
- Public Offering Price: $3.10 per share.
- Underwriting Price: $2.914 per share.
- Expected Closing Date: On or about July 24, 2013.
- Underwriters: Ladenburg Thalmann & Co. Inc. as representative.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics. It is a transactional disclosure.
Material Changes
The primary material change is the execution of an Underwriting Agreement to raise capital through the sale of new equity. The filing notes that the offering is expected to close subject to customary conditions. No prior comparable period financial data is provided in this document.
Guidance, Outlook, and Risks
Management has issued forward-looking statements regarding the offering and future operations. Key risks and contingencies identified include:
- Offering Risks: Ability to complete the offering on satisfactory terms and potential adverse impact on the market price of common stock.
- Clinical Development: Success of Phase III posterior uveitis trials and Phase II Latanoprost Product trials.
- Commercialization: Alimera's ability to finance, obtain regulatory approval, and commercialize ILUVIEN for DME in the EU and U.S., including reimbursement outcomes in the U.K.
- Partnerships: Pfizer, Inc.'s exercise of options to license the Latanoprost Product.
- Financial Health: Ability to attain profitability, obtain additional capital, and risks of further impairment of intangible assets.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received by pSivida Corp.
- Review the attached press releases (Exhibits 99.1 and 99.2) for specific use of proceeds.
- Monitor the status of the Phase III posterior uveitis trials and ILUVIEN regulatory approvals in the U.S. and EU.
- Check for any updates regarding Pfizer's option to license the Latanoprost Product.
- Confirm the impact of the new share issuance on existing shareholder dilution.